Navigation Links
Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30

CLEVELAND, Sept. 30 /PRNewswire/ -- Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators. Grants focus on researching the effects of GanedenBC30 on human immune cells. Previous studies have demonstrated the ability of GanedenBC30 to modulate numerous human immune cells, both in vitro and in vivo.

To be eligible, investigators must have a full-time faculty appointment at a research institution or medical school. Applicants must have interest in studying the effects of GanedenBC30 on human immune cells, as well as the capacity to conduct such research.

Two grants will be funded at a maximum of $15,000 for each project. Applicants will be expected to submit a budget outlining how the funds will be used. A meeting with Ganeden's Scientific Board will be required prior to the start of the research, as well as following the research to present the results. Travel for these meetings will be subsidized above the grant amount.

Applications will be reviewed by:

  • Ken Alibek, CEO, AFG Bioscience
  • John Endres, chief scientific officer, AIBMR Life Sciences
  • Sean Farmer, chief scientific officer, Ganeden Biotech
  • Glenn Gibson, professor, University of Reading
  • Gary Huffnagle, professor, University of Michigan
  • David Keller, vice president of scientific operations, Ganeden Biotech

Grant applications will be judged on quality of the proposed experimental design, originality of the proposal, evidence of the applicant's ability to conduct the proposed research, and relevance of the proposed research to the health of the general population.

Please contact Dr. David Keller at for all requests and submission of applications. The deadline for applications is December 31, 2009.

"Ganeden Biotech is happy to announce these grants to early investigators," said Ganeden Biotech CSO and co-founder Sean Farmer. "We believe that research is core to the probiotics industry, and that these grants will enable early investigators to add to the current body of research demonstrating the health benefits of probiotics."

About Ganeden Biotech

Founded in 1996, Ganeden Biotech Inc. is a private company based in Cleveland, Ohio, and is the largest seller of over-the-counter probiotics in the U.S. through its Digestive Advantage and Sustenex brands. It also licenses its patented probiotic bacteria, GanedenBC30, for use in commercial food and beverage applications as well as in medical foods and dietary supplements. GanedenBC30 was found to be Generally Recognized As Safe (GRAS) by an independent expert panel assembled to assess its safety in use as a food ingredient. Digestive Advantage and Sustenex are available at over 40,000 retailers nationwide including Wal-Mart, CVS/pharmacy, Walgreens, Rite-Aid, Stop & Shop, Giant, Publix, Kroger, and Target. For more information, visit,, or

SOURCE Ganeden Biotech Inc.

SOURCE Ganeden Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Melanoma Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC
3. Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech
4. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
5. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
6. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
7. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
8. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
9. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
10. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
11. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Post Your Comments:
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
Breaking Medicine News(10 mins):